









市場行情
/
股票
/
nasdaq-trvi
/

Trevi Therapeutics Inc

TRVI

12.850USD

-0.120-0.93%

收盤 12/26, 16:00（美東）報價延遲15分鐘

1.65B總市值

虧損本益比TTM



Trevi Therapeutics Inc

12.850

-0.120-0.93%

概覽公司財務分析

概覽

公司

財務

分析

關於 Trevi Therapeutics Inc 公司

Trevi Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of the investigational therapy Haduvio (oral nalbuphine ER) for the treatment of chronic cough in patients with idiopathic pulmonary fibrosis (IPF), chronic cough in patients with non-IPF interstitial lung disease, and refractory chronic cough. Haduvio is an oral extended-release (ER) formulation of nalbuphine. Nalbuphine is a mixed kappa-opioid receptor agonist and mu-opioid receptor antagonist. It has conducted a Phase II clinical trial and an open-label extension study of Haduvio in pruritus in patients with prurigo nodularis and a Phase IIb/III clinical trial. The Company’s Haduvio development programs include Chronic Cough in IPF Program, RCC Program, and Prurigo Nodularis Program. The Company’s subsidiary is Trevi Therapeutics Limited.

Trevi Therapeutics Inc簡介



公司代碼TRVI

公司名稱Trevi Therapeutics Inc

上市日期May 07, 2019

CEOGood (Jennifer L)

員工數量26

證券類型Ordinary Share

年結日May 07

公司地址195 Church Street

城市NEW HAVEN

上市交易所NASDAQ OMX - NASDAQ BASIC

國家United States of America

郵編06510

電話12033042499

網址https://www.trevitherapeutics.com/

公司代碼TRVI

上市日期May 07, 2019

CEOGood (Jennifer L)

Trevi Therapeutics Inc公司高管



名稱

名稱/職務

職務

持股

持股變動

Dr. David P. Meeker, M.D.

Independent Chairman of the Board

352.49K

Dr. Thomas R. Sciascia, M.D.

Co-Founder, Chief Scientific Officer

214.43K

Ms. Jennifer L. Good

President, Chief Executive Officer, Director

213.31K

Dr. Farrell Simon, Pharm.D.

Chief Commercial Officer

76.90K

+68.46%

Ms. Anne M. Vanlent

Independent Director

25.98K

Mr. Michael Thomas (Mike) Heffernan

Independent Director

6.35K

Dr. James V. (Jim) Cassella, Ph.D.

Chief Development Officer

Mr. Dominick C. Colangelo

Independent Director

Mr. Edward T. Mathers

Independent Director

Jonathan Carlson

IR Contact Officer

名稱

名稱/職務

職務

持股

持股變動

Dr. David P. Meeker, M.D.

Independent Chairman of the Board

352.49K

Dr. Thomas R. Sciascia, M.D.

Co-Founder, Chief Scientific Officer

214.43K

Ms. Jennifer L. Good

President, Chief Executive Officer, Director

213.31K

Dr. Farrell Simon, Pharm.D.

Chief Commercial Officer

76.90K

+68.46%

Ms. Anne M. Vanlent

Independent Director

25.98K

Mr. Michael Thomas (Mike) Heffernan

Independent Director

6.35K

收入明細

由於公司未披露，未能獲取相關數據

由於公司未披露，未能獲取相關數據

業務

地區

由於公司未披露，未能獲取相關數據

股東統計

更新時間: 11月16日週日

持股股東

股東類型

持股股東

佔比

New Enterprise Associates (NEA)

10.31%

Frazier Life Sciences Management, L.P.

8.00%

Rubric Capital Management LP

6.65%

BlackRock Institutional Trust Company, N.A.

5.75%

The Vanguard Group, Inc.

4.53%

其他

64.76%

持股股東

佔比

New Enterprise Associates (NEA)

10.31%

Frazier Life Sciences Management, L.P.

8.00%

Rubric Capital Management LP

6.65%

BlackRock Institutional Trust Company, N.A.

5.75%

The Vanguard Group, Inc.

4.53%

其他

64.76%

股東類型

持股股東

佔比

Investment Advisor

28.04%

Investment Advisor/Hedge Fund

24.51%

Venture Capital

17.14%

Hedge Fund

16.47%

Private Equity

10.58%

Research Firm

5.74%

Individual Investor

0.76%

Pension Fund

0.37%

Bank and Trust

0.27%

機構持股



更新時間: 10月1日週三

報告期間

機構數

持股數

持股佔比

持股變動

2025Q3

272

116.14M

95.37%

+14.43M

2025Q2

232

94.28M

77.42%

+5.93M

2025Q1

226

89.66M

76.74%

+2.50M

2024Q4

177

80.67M

91.74%

+11.34M

2024Q3

156

59.14M

78.18%

-6.31M

2024Q2

148

56.93M

80.80%

-4.85M

2024Q1

147

52.57M

76.38%

-8.69M

2023Q4

131

54.54M

85.48%

-544.63K

2023Q3

124

54.64M

88.55%

-1.52M

2023Q2

115

54.75M

93.54%

+3.66M

股東持股明細



名稱

持股數

佔比

持股變動

變動比例

公告日期

New Enterprise Associates (NEA)

11.37M

9.34%

-1.85M

-14.01%

Aug 11, 2025

Frazier Life Sciences Management, L.P.

10.26M

8.42%

Jun 30, 2025

Rubric Capital Management LP

8.53M

7.01%

+3.99M

+87.99%

Jun 30, 2025

BlackRock Institutional Trust Company, N.A.

5.65M

4.64%

+1.10M

+24.11%

Jun 30, 2025

The Vanguard Group, Inc.

5.32M

4.37%

+1.48M

+38.53%

Jun 30, 2025

Vivo Capital, LLC

4.49M

3.69%

+1.00M

+28.67%

Jun 30, 2025

Marshall Wace LLP

2.48M

2.03%

-76.31K

-2.99%

Jun 30, 2025

AllianceBernstein L.P.

4.28M

3.52%

+4.26M

+19064.53%

Jun 30, 2025

持股ETF



更新時間: 12月2日週二

機構名稱

佔比

State Street SPDR S&P Pharmaceuticals ETF

1.91%

Direxion Daily Pharmaceutical & Medical Bl 3X ETF

1.36%

Invesco Dorsey Wright Healthcare Momentum ETF

1.3%

ALPS Medical Breakthroughs ETF

0.59%

Invesco Dorsey Wright SmallCap Momentum ETF

0.54%

Optimize Strategy Index ETF

0.37%

Vanguard US Momentum Factor ETF

0.22%

iShares Micro-Cap ETF

0.2%

Vanguard US Minimum Volatility ETF

0.18%

ProShares Ultra Nasdaq Biotechnology

0.14%

State Street SPDR S&P Pharmaceuticals ETF

佔比1.91%

Direxion Daily Pharmaceutical & Medical Bl 3X ETF

佔比1.36%

Invesco Dorsey Wright Healthcare Momentum ETF

佔比1.3%

ALPS Medical Breakthroughs ETF

佔比0.59%

Invesco Dorsey Wright SmallCap Momentum ETF

佔比0.54%

Optimize Strategy Index ETF

佔比0.37%

Vanguard US Momentum Factor ETF

佔比0.22%

iShares Micro-Cap ETF

佔比0.2%

Vanguard US Minimum Volatility ETF

佔比0.18%

ProShares Ultra Nasdaq Biotechnology

佔比0.14%

分紅派息



近5年累計派現 0.00 美元

公告日期

分紅計劃

股權登記日

現金發放日

除權除息日

暫無數據

拆合股



公告日期

類型

比率

暫無數據

公告日期

類型

比率

暫無數據

常見問題

Trevi Therapeutics Inc的前五大股東是誰？



Trevi Therapeutics Inc的前五大股東如下：
New Enterprise Associates (NEA)
持有股份：11.37M
佔總股份比例：9.34%。
Frazier Life Sciences Management, L.P.
持有股份：10.26M
佔總股份比例：8.42%。
Rubric Capital Management LP
持有股份：8.53M
佔總股份比例：7.01%。
BlackRock Institutional Trust Company, N.A.
持有股份：5.65M
佔總股份比例：4.64%。
The Vanguard Group, Inc.
持有股份：5.32M
佔總股份比例：4.37%。